[1] P.G. Kopelman, Obesity as a medical problem, Nature 404 (2000) 635–643.
[2] P. Zimmet, Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? J. Intern. Med. 247 (2000) 301–310.
[3] P. Zimmet, K.G. Alberti, J. Shaw, Global and societal implications of the diabetes epidemic, Nature 414 (2001) 782–787.
[4] B.B. Lowell, G.I. Shulman, Mitochondrial dysfunction and type 2 diabetes, Science 307 (2005) 384–387.
[5] P. Dandona, A. Aljada, A. Bandyopadhyay, Inflammation: the link between insulin resistance, obesity and diabetes, Trends Immunol. 25 (2004) 4–7.
[6] Y. Yagishita, A. Uruno, T. Fukutomi, R. Saito, D. Saigusa, J. Pi, A. Fukamizu, F. Sugiyama, S. Takahashi, M. Yamamoto, Nrf2 improves leptin and insulin resistance provoked by hypothalamic oxidative stress, Cell Rep. 18 (2017) 2030–2044.
[7] J. Ye, Mechanisms of insulin resistance in obesity, Front. Med. 7 (2013) 14–24.
[8] A.J. Cruz-Jentoft, A.A. Sayer, Sarcopenia, Lancet 393 (2019) 2636–2646.
[9] S. Shibata, A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice, Yakugaku Zasshi 120 (2000) 849–862.
[10] M. Kuroda, Y. Mimaki, Y. Sashida, T. Mae, H. Kishida, T. Nishiyama, M. Tsukagawa, E. Konishi, K. Takahashi, T. Kawada, K. Nakagawa, M. Kitahara, Phenolics with PPAR-gamma ligand-binding activity obtained from licorice (Glycyrrhiza uralensis roots) and ameliorative effects of glycyrin on genetically diabetic KK-A(y) mice, Bioorg. Med. Chem. Lett. 13 (2003) 4267–4272.
[11] T.Y. Wu, T.O. Khor, C.L. Saw, S.C. Loh, A.I. Chen, S.S. Lim, J.H. Park, L. Cai, A. regulation of Nrf2-mediated genes by non-polar fractions of tea Chrysanthemum zawadskii and licorice Glycyrrhiza uralensis, AAPS J. 13 (2011) 1–13.
[12] H. Haraguchi, N. Yoshida, H. Ishikawa, Y. Tamura, K. Mizutani, T. Kinoshita, Protection of mitochondrial functions against oxidative stresses by isoflavans from Glycyrrhiza glabra, J. Pharm. Pharmacol. 52 (2000) 219–223.
[13] T. Fukai, A. Marumo, K. Kaitou, T. Kanda, S. Terada, T. Nomura, Anti-Helicobacter pylori flavonoids from licorice extract, Life Sci. 71 (2002) 1449–1463.
[14] C.K. Lee, K.K. Park, S.S. Lim, J.H. Park, W.Y. Chung, Effects of the licorice extract against tumor growth and cisplatin-induced toxicity in a mouse xenograft model of colon cancer, Biol. Pharm. Bull. 30 (2007) 2191–2195.
[15] K. Nakagawa, M. Kitano, H. Kishida, T. Hidaka, K. Nabae, M. Kawabe, K. Hosoe, 90-Day repeated-dose toxicity study of licorice flavonoid oil (LFO) in rats, Food Chem. Toxicol. 46 (2008) 2349–2357.
[16] K. Nakagawa, H. Kishida, N. Arai, T. Nishiyama, T. Mae, Licorice flavonoids suppress abdominal fat accumulation and increase in blood glucose level in obese diabetic KK-A(y) mice, Biol. Pharm. Bull. 27 (2004) 1775–1778.
[17] F. Aoki, S. Honda, H. Kishida, M. Kitano, N. Arai, H. Tanaka, S. Yokota, K. Nakagawa, T. Asakura, Y. Nakai, T. Mae, Suppression by licorice flavonoids of abdominal fat accumulation and body weight gain in high-fat diet-induced obese C57BL/6J mice, Biosci. Biotechnol. Biochem. 71 (2007) 206–214.
[18] Y. Tominaga, K. Nakagawa, T. Mae, M. Kitano, S. Yokota, T. Arai, H. Ikematsu, S. Inoue, Licorice flavonoid oil reduces total body fat and visceral fat in overweight subjects: a randomized, double-blind, placebo-controlled study, Obes. Res. Clin. Pract. 3 (2009) I–IV.
[19] M. Kuroda, Y. Mimaki, S. Honda, H. Tanaka, S. Yokota, T. Mae, Phenolics from Glycyrrhiza glabra roots and their PPAR-gamma ligand-binding activity, Bioorg. Med. Chem. 18 (2010) 962–970.
[20] Y. Yoshioka, Y. Yamashita, H. Kishida, K. Nakagawa, H. Ashida, Licorice flavonoid oil enhances muscle mass in KK-A(y) mice, Life Sci. 205 (2018) 91–96.
[21] K. Sawada, Y. Yamashita, T. Zhang, K. Nakagawa, H. Ashida, Glabridin induces glucose uptake via the AMP-activated protein kinase pathway in muscle cells, Mol. Cell. Endocrinol. 393 (2014) 99–108.
[22] M. Nishimura, Breeding of mice strains for diabetes mellitus, Exp. Anim. 18 (1969) 147–157.
[23] A.J. King, The use of animal models in diabetes research, Br. J. Pharmacol. 166 (2012) 877–894.
[24] Z. Xu, J. Huo, X. Ding, M. Yang, L. Li, J. Dai, K. Hosoe, H. Kubo, M. Mori, K. Higuchi, J. Sawashita, Coenzyme Q10 improves lipid metabolism and ameliorates obesity by regulating CaMKII-mediated PDE4 inhibition, Sci. Rep. 7 (2017) 8253.
[25] M. Kitada, Y. Ogura, D. Koya, Rodent models of diabetic nephropathy: their utility and limitations, Int. J. Nephrol. Renov. Dis. 9 (2016) 279–290.
[26] S.A. Bustin, V. Benes, J. Garson, J. Hellemans, J. Huggett, M. Kubista, R. Mueller, T. Nolan, M.W. Pfaffl, G. Shipley, C.T. Wittwer, P. Schjerling, P.J. Day, M. Abreu, B. Aguado, J.F. Beaulieu, A. Beckers, S. Bogaert, J.A. Browne, F. Carrasco-Ramiro, L. Ceelen, K. Ciborowski, P. Cornillie, S. Coulon, A. Cuypers, S. De Brouwer, L. De Ceuninck, J. De Craene, H. De Naeyer, W. De Spiegelaere, K. Deckers, A. Dheedene, K. Durinck, M. Ferreira-Teixeira, A. Fieuw, J.M. Gallup, S. Gonzalo-Flores, K. Goossens, F. Heindryckx, E. Herring, H. Hoenicka, L. Icardi, R. Jaggi, F. Javad, M. Karampelias, F. Kibenge, M. Kibenge, C. Kumps, I. Lambertz, T. Lammens, A. Markey, P. Messiaen, E. Mets, S. Morais, A. Mudarra-Rubio, J. Nakiwala, H. Nelis, P.A. Olsvik, C. P´erez-Novo, M. Plusquin, T. Remans, A. Rihani, P. Rodrigues-Santos, P. Rondou, R. Sanders, K. Schmidt-Bleek, K. Skovgaard, K. Smeets, L. Tabera, S. Toegel, T. Van Acker, W. Van den Broeck, J. Van der Meulen, M. Van Gele, G. Van Peer, M. Van Poucke, N. Van Roy, S. Vergult, J. Wauman, M. Tshuikina-Wiklander, E. Willems, S. Zaccara, F. Zeka, J. Vandesompele, The need for transparency and good practices in the qPCR literature, Nat. Methods 10 (2013) 1063–1067.
[27] M. Miyazaki, H. Sampath, X. Liu, M.T. Flowers, K. Chu, A. Dobrzyn, J.M. Ntambi, Stearoyl-CoA desaturase-1 deficiency attenuates obesity and insulin resistance in leptin-resistant obese mice, Biochem. Biophys. Res. Commun. 380 (2009) 818–822.
[28] J.M. Ntambi, M. Miyazaki, J.P. Stoehr, H. Lan, C.M. Kendziorski, B.S. Yandell, Y. Song, P. Cohen, J.M. Friedman, A.D. Attie, Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity, Proc. Natl. Acad. Sci. USA 99 (2002) 11482–11486.
[29] J.M. Ntambi, M. Miyazaki, Regulation of stearoyl-CoA desaturases and role in metabolism, Prog. Lipid Res. 43 (2004) 91–104.
[30] G. Jiang, Z. Li, F. Liu, K. Ellsworth, Q. Dallas-Yang, M. Wu, J. Ronan, C. Esau, C. Murphy, D. Szalkowski, R. Bergeron, T. Doebber, B.B. Zhang, Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase- 1, J. Clin. Investig. 115 (2005) 1030–1038.
[31] R. Guti´errez-Ju´arez, A. Pocai, C. Mulas, H. Ono, S. Bhanot, B.P. Monia, L. Rossetti, Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance, J. Clin. Investig. 116 (2006) 1686–1695.
[32] M. Miyazaki, M.T. Flowers, H. Sampath, K. Chu, C. Otzelberger, X. Liu, J. M. Ntambi, Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis, Cell Metab. 6 (2007) 484–496.
[33] S.H. Lee, A. Dobrzyn, P. Dobrzyn, S.M. Rahman, M. Miyazaki, J.M. Ntambi, Lack of stearoyl-CoA desaturase 1 upregulates basal thermogenesis but causes hypothermia in a cold environment, J. Lipid Res. 45 (2004) 1674–1682.
[34] M.T. Flowers, J.M. Ntambi, Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism, Curr. Opin. Lipidol. 19 (2014) 248–256.
[35] P. Dobrzyn, A. Dobrzyn, M. Miyazaki, P. Cohen, E. Asilmaz, D.G. Hardie, J. M. Friedman, J.M. Ntambi, Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver, Proc. Natl. Acad. Sci. USA 101 (2004) 6409–6414.
[36] A.L. AM, D.N. Syed, J.M. Ntambi, Insights into stearoyl-CoA desaturase-1 regulation of systemic metabolism, Trends Endocrinol. Metab. 28 (2017) 831–842.
[37] A.M. Hebbachi, B.L. Knight, D. Wiggins, D.D. Patel, G.F. Gibbons, Peroxisome proliferator-activated receptor α deficiency abolishes the response of lipogenic gene expression to re-feeding, Biol. Chem. 283 (2008) 4866–4876.
[38] S. Zhang, M.W. Hulver, R.P. McMillan, M.A. Cline, E.R. Gilbert, The pivotal role of pyruvate dehydrogenase kinases in metabolic flexibility, Nutr. Metab. 11 (2014) 10 (Lond.).
[39] J.E. Foley, Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus, Diabetes Care 15 (1992) 773–784.
[40] L. Hue, H. Taegtmeyer, The Randle cycle revisited: a new head for an old hat, Am. J. Physiol. Endocrinol. Metab. 297 (2009) E578–E591.
[41] B. Hwang, N.H. Jeoung, R.A. Harris, Pyruvate dehydrogenase kinase isoenzyme 4 (PDHK4) deficiency attenuates the long-term negative effects of a high-saturated fat diet, Biochem. J. 423 (2009) 243–252.
[42] R. Tao, X. Xiong, R.A. Harris, M.F. White, X.C. Dong, Genetic inactivation of pyruvate dehydrogenase kinases improves hepatic insulin resistance induced diabetes, PLoS One 8 (2013) 71997.
[43] S. Nishimura, I. Manabe, M. Nagasaki, K. Eto, H. Yamashita, M. Ohsugi, M. Otsu, K. Hara, K. Ueki, S. Sugiura, K. Yoshimura, T. Kadowaki, R. Nagai, CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity, Nat. Med. 15 (2009) 914–920.
[44] H. Kwon, J.E. Pessin, Adipokines mediate inflammation and insulin resistance, Front. Endocrinol. 4 (2013) 71 (Lausanne).
[45] J.W. Lee, S.S. Choe, H. Jang, J. Kim, H.W. Jeong, H. Jo, K.H. Jeong, S. Tadi, M. G. Park, T.H. Kwak, J. Man Kim, D.H. Hyun, J.B. Kim, AMPK activation with glabridin ameliorates adiposity and lipid dysregulation in obesity, J. Lipid Res. 53 (2012) 1277–1286.
[46] Y. Yamashita, H. Kishida, K. Nakagawa, Y. Yoshioka, H. Ashida, Liquorice flavonoid oil suppresses hyperglycaemia accompanied by skeletal muscle myocellular GLUT4 recruitment to the plasma membrane in KK-A(y) mice, Int. J. Food Sci. Nutr. 70 (2019) 294–302.
[47] A. Hattori, M. Takemoto, T. Ishikawa, Y. Maezawa, M. Koshizaka, H. Tokuyama, P. He, H. Kawamura, K. Kobayashi, K. Yokote, Metabolic effects of glabridin in healthy volunteers and patients with type 2 diabetes: a pilot study, Cogent Food Agric. 5 (2019), 1665943.
[48] S.J. Wakil, L.A. Abu-Elheiga, Fatty acid metabolism: target for metabolic syndrome, J. Lipid Res. Suppl. 50 (2009) S138–S143.
[49] M. Roden, G.I. Shulman, The integrative biology of type 2 diabetes, Nature 576 (2019) 51–60.
論文の公開元へ
